Fintel reports that on October 10, 2025, Morgan Stanley maintained coverage of Vertex Pharmaceuticals (NasdaqGS:VRTX) with a Equal-Weight recommendation. Analyst Price Forecast Suggests 18.17% Upside ...

Morgan Stanley lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $438 from $439 and keeps an Equal Weight rating on the shares.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class profile--The AATD ...

Matt Deitke, a 24-year-old AI prodigy, was recently hired at a record US$250 million (roughly Rs.2250 crores), payable over four years, by Meta Platforms Inc. Deitke had turned down Meta’s initial ...

Unlike peers, GSK plc faces limited Loss of Exclusivity risk, supporting steady revenue projections and justifying higher ...

As the biotech industry undergoes a reset, the Business Journal’s 2025 honorees shared advice from their careers.

Capital Group Dividend Value ETF ranked among the top performers within the dividend ETF category since its inception. Learn ...

SNS Insider projects the U.S. Drug Discovery Market to grow from USD 24.53 Billion in 2025 to USD 48.97 Billion by 2033, at a CAGR of 9.74%.Austin, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Drug Discovery ...

TIME Magazine announces its Top 300 Best Inventions of 2025 (one North Vancouver company recognized) Vancouver, BC, October ...